nach oben

Die Pathologie

Erschienen in:

20.04.2021 | Hypophysenadenome | CME

WHO-Klassifikation der Hypophysentumoren des Jahres 2017

verfasst von: Prof. Dr. Wolfgang Saeger

Erschienen in: Die Pathologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die WHO-Klassifikation der Hypophysentumoren aus dem Jahr 2017 basiert bez. der Adenome weiterhin auf Strukturanalysen und der immunhistologischen Expressionen hypophysärer Hormone, aber als erster entscheidender Neuerung auch auf der Expression der 3 hypophysären Transkriptionsfaktoren Pit‑1, T‑Pit und SF‑1. Die 2. Neuerung ist der Ersatz des Begriffs „atypisches Adenom“ durch „aggressives Adenom“. Die 3. Neuerung betrifft die 3 neurohypophysären Tumoren Pituizytome, Spindelzellonkozytome und Granularzelltumoren, die durch ihre gemeinsame TTF-1-Expression definiert sind. Die Kraniopharyngeome lassen sich als adamantinomatöser Subtyp durch ihren fokalen nukleären β‑Catenin-Nachweis und als papillarer Subtyp durch den BRAF(V600E)-Mutationsnachweis identifizieren. Weitere primär hypophysäre Tumoren sind extrem selten. Sie sind ebenso wie die Tumoren der Sellaregion nahezu immer im Zweifelsfall mit immunhistologischen Methoden von Hypophysentumoren sicher unterscheidbar.

Saeger W, Koch A (2021) Review: clinical implications of the new WHO classification 2017 for pituitary tumors. Exp Clin Endocrinol Diabetes 129:146–156PubMed

Souchier C, Guigard MP, Fonlupt P, Trouillas J (1996) Quantitative evaluation of the distribution of cell density—application to human pituitary corticotroph cells. Anal Quant Cytol Histol 18:251–260PubMed

McKeever PE, Koppelman MCS, Metcalf D, Quindlen E, Kornblith PL, Strott CA, Howard R, Smith BH (1982) Refractory cushing’s disease caused by multinodular ACTH-cell hyperplasia. J Neuropathol Exp Neurol 41:490–499PubMed

Scheithauer BW, Kovacs K, Randall RV (1983) The pituitary gland in untreated Addison’s disease. A histologic and immunocytologic study of 18 adenohypophyses. Arch Pathol Lab Med 107:484–487PubMed

Scheithauer BW, Kovacs K, Randall RV, Ryan N (1985) Pituitary gland in hypothyroidism. Histologic and immunocytologic study. Arch Pathol Lab Med 109:499–504PubMed

Saeger W, Schröder H (1985) ACTH-Zellhyperplasien der Adeno- und der Neurohypophyse und ihre Beziehungen zur arteriellen Hypertonie. Pathologe 6:141–148PubMed

Asa SL (1998) Tumors of the pituitary gland. Armed Forces Institute of Pathology, Washington, D.C., S 1–210

Kovacs K, Horvath E (1986) Tumors of the pituitary gland. Armed Forces Institute of Pathology, Washington, D.C., S 1–269

Lloyd RV, Kovacs K, Young WF Jr., Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, Watson RE Jr., Lindell EP, Barkan AL, Saeger W, Nosé V, Osamura RY, Ezzat S, Yamada S, Roncaroli F, Lopes MBS, Ruibal VS (2004) Tumours of the pituitary. In: DeLellis RA, Lloyd RV, Heitz PU (Hrsg) Pathology and Genetics. Tumours of Endocrine Tumours, 1. Aufl. IARC, Lyon, S 9–48

10.

Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP (1993) Cell type-specific expression of the pituitary transcription activator pit‑1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 77:1275–1280PubMed

11.

Sjöstedt E, Bollerslev J, Mulder J, Lindskog C, Ponten F, Casar-Borota O (2017) A specific antibody to detect transcription factor T‑pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol. https://doi.org/10.1007/s00401-017-1768-9CrossRefPubMed

12.

Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S (1996) The transcription activator steroidogenic factor‑1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 81:2165–2170PubMed

13.

Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228–243PubMed

14.

Saeger, W, Buslei, R: Data of the German Pituitary Tumor Registry in 2018 according to the new WHO classification of 2017, 2020. (UnPub)

15.

Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL (1995) Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80:3621–3627PubMed

16.

Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, Weiss MH (1981) Acidophil stem-cell adenoma of the human pituitary—clinicopathologic analysis of 15 cases. Cancer 47:761–771PubMed

17.

Amlashi FG, Tritos NA (2016) Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine 52:427–440PubMed

18.

Scheithauer BW, Horvath E, Lloyd RV, Kovacs K (2001) Pathology of pituitary adenomas and pituitary hyperplasia. In: Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (Hrsg) Diagnosis and management pituitary tumors, 1. Aufl. Humana Press, Totowa, S 91–154

19.

Horvath E, Kovacs K (1991) The adenohypophysis. In: Kovacs K, Asa SL (Hrsg) Functional endocrine pathology. Blackwell, Oxford, London, Edinburgh, Melbourne, Paris, Berlin, Vienna, S 245–282

20.

Saeger W, Lüdecke DK (1982) Pituitary adenomas with hyperfunction of TSH. Frequency, histological classification, immunocytochemistry and ultrastructure. Virchows Arch 394:255–267

21.

Crooke AC (1935) A change in the basophil cells of the pituitary gland common to conditions which wxhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 41:339–349

22.

DeLellis RA, Lloyd RV, Heitz PU (2004) Pathology and genetics: Tumours of endocrine organs (World Health Organization classification of tumours), 1. Aufl. International Agency for Research and Cancer (IARC), Lyon, S 1–311

23.

Landolt AM, Heitz PU (1986) Alpha-subunit-producing pituitary adenomas. Immunocytochemical and ultrastructural studies. Virchows Arch A Pathol Anat Histopathol 409:417–431PubMed

24.

Saeger W (2015) Hypophyse. In: Amann K, Kain R, Klöppel G (Hrsg) Urogenitale und endokrine Organe, Gelenke und Skelett, 3. Aufl. Springer, Heidelberg, S 587–630

25.

Osamura R, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Tumours of the pituitary gland. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (Hrsg) WHO classification of tumours of endocrine organs, 4. Aufl. Springer, Heidelberg, Berlin, S 11–64

26.

Manojlovic-Gacic E, Engstrom B, Casar-Borota O (2018) Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary 21:119–129PubMed

27.

Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, White WL, Mooney MA, Bernat AL, Mete O, Zadeh G, Gentili F, Little AS (2019) Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22:514–519PubMed

28.

Balogun JA, Monsalves E, Juraschka K, Parvez K, Kucharczyk W, Mete O, Gentili F, Zadeh G (2015) Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol 26:63–70PubMed

29.

Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—Immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511–524PubMed

30.

Stefaneanu L, Kovacs K, Horvath E, Scheithauer BW (2000) The adenohypophysis. In: Stefaneanu L, Sasano H, Kovacs K (Hrsg) Molecular and cellular endocrine pathology, 1. Aufl. Arnold, London, S 75–118

31.

Nakhleh A, Shehadeh N, Hochberg I, Zloczower M, Zolotov S, Taher R, Naccache DD (2018) Management of cystic prolactinomas: a review. Pituitary 21:425–430PubMed

32.

Lee EH, Kim KH, Kwon JH, Kim HD, Kim YZ (2014) Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma. World Neurosurg 81:563–575PubMed

33.

Coli A, Asa SL, Fadda G, Scannone D, Chiloiro S, de Marinis L, Lauretti L, Ranelletti FO, Lauriola L (2016) Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. Eur J Endocrinol 174:307–314PubMed

34.

Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas-diagnosis and emerging treatments. Nat Rev Endocrinol 10:423–435PubMed

35.

Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course-case report and review of the literature. J Clin Endocrinol Metab 96:2665–2669PubMed

36.

Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24:C5–C8PubMed

37.

Saeger W, Lüdecke DK, Losa M (1997) Kombinierte neuronale und endokrine Tumoren der Sellaregion. Pathologe 18:419–424PubMed

38.

Saeger W, Puchner MJA, Lüdecke DK (1994) Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing’s disease. A report of 3 cases. Virchows Arch 425:93–99PubMed

39.

Sergeant C, Jublanc C, Leclercq D, Boch AL, Bielle F, Raverot G, Daly AF, Trouillas J, Villa C (2017) Transdifferentiation of neuroendocrine cells gangliocytoma associated with two pituitary adenomas of different lineage in MEN1. Am J Surg Pathol 41:849–853PubMed

40.

Pereira SS, Monteiro MP, Costa MM, Moreira A, Alves MG, Oliveira PF, Jarak I, Pignatelli D (2019) IGF2 role in adrenocortical carcinoma biology. Endocrine 66:326–337PubMedPubMedCentral

41.

Maguire JA, Bilbao JM, Kovacs K, Resch L (1992) Hypothalamic neurocytoma with vasopressin Immunoreactivity—Immunohistochemical and ultrastructural observations. Endocr Pathol 3:99–104PubMed

42.

Lach B, Rippstein P, Benoit BG, Staines W (1996) Differentiating neuroblastoma of pituitary gland: Neuroblastic transformation of epithelial adenoma cells—Case report. J Neurosurg 85:953–960PubMed

43.

Albert A, Ramirez JAR, Codere F, Petrecca K (2011) Sellar paraganglioma: a unique route to a rare destination case report and literature review. Clin Neurol Neurosurg 113:675–677PubMed

44.

Ghayee HK, Rege J, Watumull LM, Nwariaku FE, Carrick KS, Rainey WE, Miller WL, Auchus RJ (2011) Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. J Clin Endocrinol Metab 96:E243–E250PubMed

45.

Buslei R, Hölsken A, Hofmann B, Kreutzer J, Siebzehnrubl F, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Blümcke I (2007) Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol 113:585–590PubMed

46.

Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J, Fahlbusch R (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589–597PubMed

47.

Hofmann BM, Kreutzer J, Saeger W, Buchfelder M, Blumcke I, Fahlbusch R, Buslei R (2006) Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and Rathke cleft cysts: a clinico-pathologic approach. Am J Surg Pathol 30:1595–1603PubMed

48.

Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001PubMedPubMedCentral

49.

Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, Takeuchi Y, Nakasu S, Okabe H (2010) Malignant transformation in craniopharyngioma after radiation therapy: a case report and review of the literature. Clin Neuropathol 29:A2–A8

50.

Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S, Piepgras DG (2007) The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 31:1020–1028PubMed

51.

Sofela AA, Hettige S, Curran O, Bassi S (2014) Malignant transformation in craniopharyngiomas. Neurosurgery 75:306–314PubMed

52.

Cao J, Lin JP, Yang LX, Chen K, Huang ZS (2010) Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas. Br J Neurosurg 24:249–256PubMed

53.

Brastianos PK, Santagata S (2016) BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol 174:R139–R144PubMed

54.

Schweizer L, Capper D, Holsken A, Fahlbusch R, Flitsch J, Buchfelder M, Herold-Mende C, von Deimling A, Buslei R (2015) BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke’s cleft cysts. Neuropathol Appl Neurobiol 41:733–742PubMed

55.

Hama S, Arita K, Nishisaka T, Fukuhara T, Tominaga A, Sugiyama K, Yoshioka H, Eguchi K, Sumida M, Heike Y, Kurisu K (2002) Changes in the epithelium of Rathke cleft cyst associated with inflammation. J Neurosurg 96:209–216PubMed

56.

Daggett GJ, Wood JS, Gumber S, Pinelli CJ (2020) Spontaneous pituitary adenomas in squirrel monkeys (Saimiri sciureus). comp med 70:83–86PubMed

57.

Hasiloglu ZI, Ure E, Comunoglu N, Tanriover N, Oz B, Gazioglu N, Mihmanli I (2016) New radiological clues in the diagnosis of spindle cell oncocytoma of the adenohypophysis. Clin Radiol 71:E5

58.

Mete O, Lopes MB, Asa SL (2013) Spindle cell Oncocytomas and granular cell tumors of the pituitary are variants of Pituicytoma. Am J Surg Pathol 37:1694–1699PubMed

59.

Roncaroli F, Scheithauer BW, Cenacchi G, Horvath E, Kovacs K, Lloyd RV, Abell-Aleff P, Santi M, Yates AJ (2002) Spindle cell oncocytoma’ of the adenohypophysis—A tumor of folliculostellate cells? Am J Surg Pathol 26:1048–1055PubMed

60.

Witte HM, Riecke A, Saeger W, Hackenbroch C, Mathieu R, Mauer UM, Schulz C (2018) Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and Epithrelial Membrane Antigen (EMA). Br J Neurosurg 15:1–6

61.

McKeever PE, Blaivas M, Sima AAF (1993) Neoplasms of the sellar region. In: Lloyd RV (Hrsg) Surgical pathology of the pituitary gland. W.B. Saunders Company, Philadelphia, S 141–210

62.

Saeger W (1981) Hypophyse. In: Doerr W, Seifert G (Hrsg) Pathologie der endokrinen Organe, Teil 2. Springer, Berlin-Heidelberg-New York, S 1–226

63.

Beems T, Grotenhuis JA, Wesseling P (1999) Meningioma of the pituitary stalk without dural attachment: case report and review of the literature. Neurosurgery 45:1474–1477PubMed

64.

Mawrin C (2019) Molekulare Biologie, Diagnostik und Therapie von Meningeomen. Pathologe 40:514–518PubMed

65.

Madsen C, Schroder HD (1997) Ki-67 immunoreactivity in meningiomas—determination of the proliferation potential of meningiomas using the monclonal antibody Ki-67. Clin Neuropathol 16:137–142PubMed

66.

Sharifi G, Bakhtevari MH, Alghasi M, Saberi M, Dehghan M, Bidari F, Rezaei O (2015) Hard calcified intrasellar schwannoma mimicking pituitary adenoma: a case report and review of the literature. Clin Neurol Neurosurg 137:38–43PubMed

67.

Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M, Puri A (2010) Revisiting Chordoma with Brachyury, a “new Age” marker analysis of a validation study on 51 cases. Arch Pathol Lab Med 134:1181–1187PubMed

68.

Jian FF, Bian LG, Sun SY, Yang J, Chen X, Chen YF, Ma QY, Miao F, Wang WQ, Ning G, Sun QF (2014) Surgical biopsies in patients with central diabetes insipidus and thickened pituitary stalks. Endocrine 47:325–335PubMed

69.

Fehn M, Bettendorf M, Lüdecke DK, Sommer C, Saeger W (1999) Lymphocytic hypophysitis masking a suprasellar germinoma in a 12 year old girl—a case report. Pituitary 1:303–307PubMed

70.

Low JCM, Maratos E, Kumar A, King A, Al-Sarraj S, Barazi S (2019) Adult Parasellar capillary Hemangioma with Intrasellar extension. World Neurosurg 124:184–191

71.

Kovacs K (1973) Metastatic cancer of the pituitary gland. Oncology 27:533–542PubMed

72.

Saeger W, Riedel M, Schröder H (1985) Metastasen in der Hypophyse und der Sella. Pathologe 6:308–312PubMed

73.

Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23–28PubMed

74.

Rotondo F, Kovacs K, Macdonald RL, Prud’homme GJ, Latta E, Munoz D (2013) Non-small cell bronchial carcinoma metastasizing into a Prolactin-producing pituitary Adenoma. Int J Surg Pathol 21:68–71PubMed

75.

Paulus W, Honegger J, Keyvani K, Fahlbusch R (1999) Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma. Acta Neuropathol 97:377–382PubMed

76.

Trifanescu R, Ansorge O, Wass JAH, Grossman AB, Karavitaki N (2012) Rathke’s cleft cysts. Clin Endocrinol 76:151–160

77.

Zada G, Lin N, Ojerholm E, Ramkissoon S, Laws ER (2010) Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships—art. no. E4. Neurosurg Focus 28:E4PubMed

78.

Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R (2004) Metastases to the pituitary in surgical specimens. Endocr Pathol 15:263–264

Titel: WHO-Klassifikation der Hypophysentumoren des Jahres 2017
verfasst von: Prof. Dr. Wolfgang Saeger
Publikationsdatum: 20.04.2021
Verlag: Springer Medizin
Schlagwörter: Hypophysenadenome
Kraniopharyngeome
Erschienen in: Die Pathologie / Ausgabe 3/2021
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-021-00932-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

WHO-Klassifikation der Hypophysentumoren des Jahres 2017

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Neues in der aktuellen WHO-Klassifikation (2020) für Weichgewebssarkome

Neue WHO-Klassifikationen und digitales Lernen

Aktuelle WHO-Klassifikation des weiblichen Genitale

Histologische Subtypen des Nierenzellkarzinoms

Mitteilungen der Deutschen Gesellschaft für Pathologie

Leitlinienbasierte Aufarbeitung und Befundung von Lymphonodektomiepräparaten und Sentinel-Lymphknoten gynäkologischer Malignome

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin